Insilico Medicine CEO touts billions in pipeline deals at BIO International Convention

At the BIO International Convention in June, Insilico Medicine chief Alex Zhavoronkov made a high‑energy appearance that attracted considerable attention.

Zhavoronkov handed out a postcard‑sized list of the company’s clinical programs, underscoring that Insilico has secured billions of dollars in pipeline deals across multiple disease areas.

He pointed out that the firm’s AI platform is presented in a web‑store‑like format, signaling the growing influence of technology on biotech development.

While he declined to discuss direct drug sales, the CEO suggested that the sheer volume of agreements positions Insilico as a rising star in AI‑driven biotechnology.